Clinical Trials Browser

Phase 1/2 × atezolizumab × Other solid neoplasm × Clear all

NCT05765084 2026-06-05

Immuno-MESODEC

Phase 1/2 Recruiting

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Wilms Tumor

NCT04896697 2026-05-05

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05434234 2025-11-10

A Study of YL201 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05109442 2025-08-20

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase 1/2 Terminated

112 enrolled 28 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1/2 Withdrawn

Other solid neoplasm

Select Advanced Solid Tumors

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04471415 2023-06-12

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT02541604 2020-02-25

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Phase 1/2 Terminated

87 enrolled 41 charts

Other solid neoplasm

Solid Tumor